Patent number: 12071477
Abstract: The present disclosure relates to antibody conjugates with binding specificity for folate receptor alpha (FOLR1) and its isoforms and homologs, and compositions comprising the antibody conjugates, including pharmaceutical compositions. The variable light chains are those of trastuzumab. Also provided are methods of producing the antibody conjugates and compositions as well as methods of using the antibody conjugates and compositions, such as in therapeutic and diagnostic methods. The antibody conjugates comprise a non-natural amino acid at a site selected from the group consisting of HC-F404, HC-K121, HC-Y180, HC-F241, HC-221, LC-T22, LC-S7, LC-N152, LC-K42, LC-E161, LC-D170, HC-S136, HC-S25, HC-A40, HC-S119, HC-S190, HC-K222, HC-R19, HC-Y52, or HC-S70, according to the Kabat, Chothia, or EU numbering scheme.
Type:
Grant
Filed:
September 17, 2018
Date of Patent:
August 27, 2024
Assignee:
SUTRO BIOPHARMA, INC.
Inventors:
Ryan Stafford, Alice Yam, Xiaofan Li, Gang Yin, Toni Kline, Cristina Abrahams, Venita De Almeida